Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
June 02, 2024 11:27 ET
|
OKX
DUBAI, United Arab Emirates, June 02, 2024 (GLOBE NEWSWIRE) -- OKX, a leading crypto exchange and Web3 technology company, has issued updates for June 2, 2024. OKX Now Supports Wormhole Protocol's...
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
June 02, 2024 10:55 ET
|
Seer, Inc.
REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that...
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test
June 02, 2024 10:00 ET
|
Precede Biosciences, Inc.
HER2 status was accurately assessed in 172 patients with advanced breast, gastroesophageal, and ovarian cancersER status was accurately assessed and the level of ER pathway activation quantified in 87...
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 02, 2024 10:00 ET
|
ALX Oncology
Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with...
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
June 02, 2024 09:51 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, June 02, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and...
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
June 02, 2024 09:01 ET
|
Celldex Therapeutics, Inc.
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data...
GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
June 02, 2024 08:23 ET
|
Robbins Geller Rudman & Dowd LLP
SAN DIEGO, June 02, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the GoodRx class action lawsuit seeks to represent purchasers or acquirers of GoodRx Holdings, Inc....
NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars
June 02, 2024 08:11 ET
|
NVIDIA
TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced the general availability of NVIDIA ACE generative AI microservices to accelerate the next wave of digital humans,...
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
June 02, 2024 08:00 ET
|
Intellia Therapeutics, Inc.
Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight of...
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
June 02, 2024 04:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., June 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence showing that patients with hereditary angioedema...